Skip to main content
Journal cover image

In a Placebo-Controlled 36-Week Phase 2 Trial, Treatment with Mgl-3196 Compared to Placebo Results in Significant Reductions in Hepatic Fat (MRI-PDFF), Liver Enzymes, Fibrosis Biomarkers, Atherogenic Lipids, and Improvement in Nash on Serial Liver Biopsy

Publication ,  Conference
Harrison, SA; Guy, CD; Bashir, M; Frias, JP; Alkhouri, N; Baum, S; Taub, RA; Moylan, CA; Bansal, MB; Neuschwander-Tetri, BA; Moussa, S
Published in: HEPATOLOGY
October 1, 2018

Duke Scholars

Published In

HEPATOLOGY

EISSN

1527-3350

ISSN

0270-9139

Publication Date

October 1, 2018

Volume

68

Start / End Page

9A / 10A

Location

San Francisco, CA

Publisher

WILEY

Conference Name

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting

Related Subject Headings

  • Gastroenterology & Hepatology
  • 3204 Immunology
  • 3202 Clinical sciences
  • 1107 Immunology
  • 1103 Clinical Sciences
  • 1101 Medical Biochemistry and Metabolomics
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Journal cover image

Published In

HEPATOLOGY

EISSN

1527-3350

ISSN

0270-9139

Publication Date

October 1, 2018

Volume

68

Start / End Page

9A / 10A

Location

San Francisco, CA

Publisher

WILEY

Conference Name

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting

Related Subject Headings

  • Gastroenterology & Hepatology
  • 3204 Immunology
  • 3202 Clinical sciences
  • 1107 Immunology
  • 1103 Clinical Sciences
  • 1101 Medical Biochemistry and Metabolomics